Connect® MM- The Multiple Myeloma Disease Registry

Celgene

Status: Terminated

Conditions: Multiple Myeloma

Treatments: Other: First-line therapy; Drug: Second-line Multiple Myeloma treatments

Study type: Observational

Funder types: Industry

Identifiers

NCT01081028

CC-5013-MM-036 (Other Identifier)

Connect ® MM

CA078-1009 (Other Identifier)

Details and patient eligibility

About

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Enrollment: 3,008 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Cohort 1 and 2

• Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
• Age ≥18 years
• Willing and able to provide signed informed consent
• Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Cohort 3

• Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
• Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
• Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

Exclusion criteria

Cohort 1 and 2

• None

Cohort 3

• Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
• Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
• Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met.
• Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

Trial design

3,008 participants in 3 patient groups

Cohort 1: Patients enrolled between Sep 2009 and Nov 2011

Description:

Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.

Treatment:

Other: First-line therapy

Cohort 2: Patients enrolled between December 2012 and mid-2016

Description:

Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016

Treatment:

Other: First-line therapy

Cohort 3: Patients enrolled from 2023

Description:

Relapsed/Refractory multiple myeloma patients receiving second-line therapy

Treatment:

Drug: Second-line Multiple Myeloma treatments